malignancy

AB1447 IMMUNE RELATED ADVERSE EVENTS DUE TO CHECKPOINT INHIBITOR THERAPY IN CANCER PATIENTS WITH RHEUMATOID ARTHRITIS: A MEDICARE CLAIMS STUDY
D. Jannat-Khah, F. Xie, A. Saxena, J. R. Curtis, A. Bass

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2081-2082; DOI: 10.1136/annrheumdis-2024-eular.4406
AB1452 HOW CANCER LOCATION AND TIMING DIFFER BETWEEN INFLAMATORY MYOPATHY AND IGA VASCULITIS
A. Hocevar, K. Perdan-Pirkmajer, Z. Rotar

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2085-2086; DOI: 10.1136/annrheumdis-2024-eular.575
AB1455 EXPLORING THE RISK, CAUSALITY RELATIONSHIP AND MOLECULAR MECHANISM BETWEEN SYSTEMIC LUPUS ERYTHEMATOSUS AND THYROID CANCER: A META, MENDELIAN RANDOMIZATION AND TRANSCRIPTOME ANALYSES
S. Liu, H. Chen, Q. Sun, Y. Liu, X. Yuan, D. Wang, L. Sun

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2087-2088; DOI: 10.1136/annrheumdis-2024-eular.1117
AB1505 INFLAMMATORY DISEASES AND RISK OF NEOPLASIA: IS IT THE TREATMENT OR THE DISEASE IN SINE? DATA ON THE MANAGEMENT OF INFLAMMATION IN CASE OF COEXISTENCE WITH MALIGNANCY
E. Pelechas, E. Kaltsonoudis, N. Koletsos, Z. Tziortzioti, A. Drosos, P. V. Voulgari

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2122-2123; DOI: 10.1136/annrheumdis-2024-eular.951
AB1537 MULTICENTRIC ANALYSIS OF RHEUMATOLOGIC ADVERSE EVENTS RELATED TO CANCER IMMUNOTHERAPY IN TWO SPANISH HOSPITALS
A. Llobell-Uriel, I. Gonzalez-Mazon, S. Retamozo, C. Secada-Gómez, A. Martín-Gutiérrez, A. García Castaño, E. Gallardo-Diaz, A. Gómez-Centeno, L. Fernandez-Morales, J. Gratacós, R. Blanco

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2139-2140; DOI: 10.1136/annrheumdis-2024-eular.5819
AB1365 SKELETAL METASTASES OF DIGESTIVE ORIGIN IN RHEUMATOLOGY: A DESCRIPTIVE STUDY OF 18 CASES
R. Ben Chehida, S. Ben Jemaa, Z. Gassara, A. Feki, M. Ezzeddine, R. Akrout, M. H. Kallel, H. Fourati, S. Baklouti

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2034-2035; DOI: 10.1136/annrheumdis-2024-eular.3882
AB1376 OSTEOARTICULAR INVOLVEMENT IN MULTIPLE MYELOMA: PREVALENCE AND RISK FACTORS
M. Dhifallah, A. Feki, S. Ben Jemaa, H. Fourati, M. H. Kallel, R. Akrout, S. Baklouti

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2040-2041; DOI: 10.1136/annrheumdis-2024-eular.752
AB1388 CLINICAL PATTERNS AND LONGTERM OUTCOMES OF ARTHRITIS INDUCED BY IMMUNE CHECKPOINT INHIBITORS. A MULTICENTER STUDY
J. A. Gómez-Puerta, A. Llobell, A. Ponce, A. Gómez-Centeno, A. M. Millán Arciniegas, H. Corominas, J. M. Nolla, J. Narváez

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 2048; DOI: 10.1136/annrheumdis-2024-eular.6167
AB1209 SYSTEMIC SCLEROSIS AND THE DEVELOPMENT OF NEOPLASMS: A SINGLE CENTER EXPERIENCE
M. Patrone, F. Riccio, M. Annunziata, M. Brancaccio, A. Citarella, M. L. Marchesano, A. Milone, C. Parlati, F. Ciccia, G. Cuomo

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1942; DOI: 10.1136/annrheumdis-2024-eular.5433
AB1175 RISK OF CANCER IN PATIENTS WITH SYSTEMIC SCLEROSIS IS INFLUENCED BY SERUM AUTOANTIBODIES, CUTANEOUS PHENOTYPE, AND IMMUNOSUPPRESSIVE THERAPIES
M. De Santis, A. Tonutti, F. Motta, A. Ceribelli, N. Isailovic, R. Ragusa, C. Selmi

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1921-1922; DOI: 10.1136/annrheumdis-2024-eular.3203

Main menu

malignancy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

malignancy

Pages